Follow us on Twitter
twitter icon@FreshPatents


Congestive Heart Failure patents

      

This page is updated frequently with new Congestive Heart Failure-related patent applications.




 Preparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure patent thumbnailPreparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure
This disclosure concerns the discovery of (r,r)- and (r,s)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


 Methods for renal neuromodulation patent thumbnailMethods for renal neuromodulation
Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease.
Medtronic Ardian Luxembourg S.a.r.l.


 Method and  performing peritoneal ultrafiltration patent thumbnailMethod and performing peritoneal ultrafiltration
Method and apparatus for ultrafiltration of a patient being overhydrated due to congestive heart failure, comprising a cassette having four inlets/outlets. A patient tube is connected to a patient connector, intended to be connected to a patient line for access to a peritoneal cavity of the patient.
Triomed Ab


 Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders patent thumbnailCo-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example nash, nafld, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (mace) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span..
Janssen Pharmaceutica Nv


 Methods and materials for treating elevated sympathetic nerve activity conditions patent thumbnailMethods and materials for treating elevated sympathetic nerve activity conditions
This document provides methods and materials involved in treating hypertension (e.g., age-associated hypertension, resistant hypertension, or chronic refractory hypertension), heart failure (e.g., congestive heart failure), or kidney disease (e.g., chronic kidney disease). For example, methods and materials involved in administering one or more sympatholytic agents to a patient to identify the patient as having an elevated baseline level of sympathetic nerve activity and treating the identified patient with a sympatholytic therapy to reduce the symptoms of hypertension (e.g., resistant hypertension), heart failure (e.g., congestive heart failure), or kidney disease (e.g., chronic kidney disease) are provided..
Mayo Foundation For Medical Education And Research


 Heteroaromatic compounds and their use as dopamine d1 ligands patent thumbnailHeteroaromatic compounds and their use as dopamine d1 ligands
And pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, impulsivity, compulsive gambling, overeating, autism spectrum disorder, mcl, age-related cognitive decline, dementia, rls, parkinson's disease, huntington's chorea, anxiety, depression, mdd, trd, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, sle, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.. .

 Prodrug of an ice inhibitor patent thumbnailProdrug of an ice inhibitor
Compound i is useful for treating il-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, alzheimer's disease, myocardial infarction, congestive heart failure, huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.. .

 Platelet rich plasma formulations patent thumbnailPlatelet rich plasma formulations
Compositions for platelet rich plasma (prp) and neutrophil-depleted prp are provided. Methods for treating ischemia damaged tissues by delivering a prp composition, in some embodiments a neutrophil-depleted prp composition to the damaged tissue are provided.

 Adjuvant therapy to standard of care (soc) diuretic treatment patent thumbnailAdjuvant therapy to standard of care (soc) diuretic treatment
A therapeutic method for treating and/or preventing diseases and medical conditions typically treated by administering diuretic agents (eg congestive heart failure). The method may comprise, for example, administering to a subject a diuretic agent in combination with vessel dilator (vsdl) or a variant or modified peptide thereof.
Madeleine Pharmaceuticals Pty Ltd


 Intrinsic frequency hemodynamic waveform analysis patent thumbnailIntrinsic frequency hemodynamic waveform analysis
Hardware and software methodology are described for cardiac health measurement. Hemodynamic waveforms variously acquired for a subject are analyzed to calculate or approximate intrinsic frequencies in two domains in two domains across the dicrotic notch.
California Institute Of Technology


Heart failure event detection using minimum heart rate

Systems, devices, or methods can be used to detect an event, or series of events, that can indicate worsening of congestive heart failure (chf), or can be used to identify a subject at an elevated risk for developing chf. A chf event predictor can be provided using a characteristic minimum of subject cardiac intervals.
Cardiac Pacemakers, Inc.

Trans-catheter ventricular reconstruction structures, methods, and systems for treatment of congestive heart failure and other conditions

Embodiments described herein include devices, systems, and methods for reducing the distance between two locations in tissue. In one embodiment, an anchor may reside within the right ventricle in engagement with the septum.
Bioventrix, Inc.

Intramyocardial patterning for global cardiac resizing and reshaping

Cardiomyopathy may be treated by distributing space-occupying agent within the myocardium in a pattern about one or more chambers of the heart, such that the space-modifying agent integrates into and thickens at least part of the cardiac wall about the chamber so as globally to reduce wall stress and stabilize or even reduce chamber size. Some patterns also cause a beneficial global reshaping of the chamber.

Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases

Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods.
Curelab Oncology, Inc.

Steerable lesion excluding heart implants for congestive heart failure

Devices, systems, and methods for treating a heart of a patient may make use of one or more implant structures which limit a size of a chamber of the heart, such as by deploying a tensile member to bring a wall of the heart toward (optionally into contact with) a septum of the heart.. .
Bioventrix, Inc.

Methods for renal neuromodulation

Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease.
Medtronic Ardian Luxembourg S.a.r.l.

Hemodynamic assist device

A hemodynamic flow assist device includes a miniature pump, a basket-like cage enclosing and supporting the pump, and a motor to drive the pump. The device is implanted and retrieved in a minimally invasive manner via percutaneous access to a patient's artery.
Hridaya, Inc.

Novel prodrug salts

Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions.
Aeromics, Inc.

Methods and compositions for treating congestive heart failure

Compositions and methods for treating congestive heart failure are provided herein.. .
The Arizona Board Of Regents On Behalf Of The University Of Arizona

Devices, creation of peripherally located fistula

Devices, systems and methods are disclosed for the formation of an arteriovenous fistula in the limb of the patient. Embodiments include a device for the creation, modification and maintenance of a fistula that includes an integral fistula creation assembly near its distal end that passes through the skin of the patient, through a first vessel such as an artery, and into a second vessel such as a vein.
Rox Medical, Inc.

Methods and renal neuromodulation

Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease.
Medtronic Ardian Luxembourg S.a.r.l.

Treatments for disorders using guanylate cyclase c agonists

The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including inflammatory bowel disease (ibd), diverticulitis, colon cancer, an inflammatory disorder, obesity, congestive heart failure, benign prostatic hyperplasia (bph), pain, salt retention or fluid retention.. .
Ironwood Pharmaceuticals, Inc

System and methods for managing congestive heart failure

The invention is a multi-purpose system and methods that focuses on the prevention of congestive heart failure (chf) exacerbations by identifying the population at risk, examining their use of medications that optimize ventricular function, tracking weight changes through different phases of illness, and retrieving vital sign and laboratory data needed for treatment intensification.. .
Stc.unm

Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunctions and congestive heart failure

In alternative embodiments, provided are methods for treating, ameliorating or protecting (preventing) congestive heart failure (chf) or a diabetes-related cardiac dysfunction, comprising: providing a urocortin 2-encoding and/or a urocortin 3-encoding nucleic acid, transcript or message, or gene, operatively linked to a transcriptional regulatory sequence, optionally contained in an expression vehicle or a vector such as an adeno-associated virus (aav), e.g., an aav8 serotype; and administering to an individual or a patient in need thereof, such as a type 2 diabetic (t2dm), e.g., by iv administration, thereby treating, ameliorating or protecting against (preventing) the t2dm and/or the diabetes-related cardiac dysfunction in the individual or patient.. .
The Regents Of The University Of California

Apj receptor compounds

The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the g protein coupled receptor apelin, also known as the apj receptor. The apj receptor compounds are derived from the it intracellular loop and domain of the apj receptor.
Anchor Therapeutics, Inc.

Peripheral blood stem cells with improved angiogenic properties and use thereof

The present application discloses a method for producing peripheral blood stem cells with improved angiogenic properties through epo or aps priming, and a use thereof. The cells produced according to the method of the present application induce angiogenesis, and thus can be effectively used for the regeneration of, or recovery from, various diseases requiring facilitation of angiogenesis, such as ischemic diseases occurring in the muscle, brain, heart, kidney, or large intestine, e.g.
Seoul National University R&db Foundation

Non-flushing niacin analogues, and methods of use thereof

One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
Trustees Of Tufts College

Graphical technique for detecting congestive heart failure

The invention provides a system to better detect the onset of congestive heart failure (chf). The system consists of two primary components—the chf index graph (chfig) and a body-worn sensor for measuring the necessary parameters—that correctly measure and analyze a set of parameters related to chf.
Tosense, Inc.

Compounds, compositions and methods

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.. .
Cytokinetics, Incorporated

Methods for treating congestive heart failure

The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.. .
The Brigham And Women's Hospital, Inc.

Methods and apparatuses for remodeling tissue of or adjacent to a body passage

Medical devices and methods for making and using the same are disclosed. An example method may include a method for treating a patient having congestive heart failure.

Methods and renal neuromodulation

Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease.

Over-the-wire cardiac implant delivery system for treatment of chf and other conditions

Medical devices, systems, and methods reduce the distance between two locations in tissue in a minimally invasive manner, often for treatment of congestive heart failure. In one embodiment, an anchor of an implant system may, when the implant system is fully deployed, reside within the right ventricle in engagement with the ventricular septum.
Bioventrix, Inc.

Graphical technique for detecting congestive heart failure

The invention provides a system to better detect the onset of congestive heart failure (chf). The system consists of two primary components—the chf index graph (chfig) and a body-worn sensor for measuring the necessary parameters—that correctly measure and analyze a set of parameters related to chf.
Tosense, Inc.

Graphical technique for detecting congestive heart failure

The invention provides a system to better detect the onset of congestive heart failure (chf). The system consists of two primary components—the chf index graph (chfig) and a body-worn sensor for measuring the necessary parameters—that correctly measure and analyze a set of parameters related to chf.
Tosense, Inc.

Highly sensitive biomarker panels

Cardiovascular disease, e.g., congestive heart failure, is often first diagnosed after the onset of clinical symptoms, eliminating potential for early intervention. The invention provides a multi-marker immunoassay, including cardiac pathology and vascular inflammation biomarkers, yielding a more sensitive assay for early detection of chf in plasma.
Singulex, Inc.

Cardiac implant migration inhibiting systems

Medical devices, systems, and methods reduce the distance between two locations in tissue, often for treatment of congestive heart failure. In one embodiment an anchor of an implant system may reside within the right ventricle in engagement with the ventricular septum.
Bioventrix, Inc.

Renal pump

Apparatus and methods are described including identifying a subject as suffering from a condition selected from the group consisting of: cardiac dysfunction, congestive heart failure, reduced renal blood flow, increased renal vascular resistance, arterial hypertension, and kidney dysfunction. In response thereto, blood pressure within a renal vein of the subject is reduced, by placing a blood pump inside the subject's renal vein and activating the impeller to pump blood from the renal vein into the subject's vena cava.
Magenta Medical Ltd.

Tissue protecting devices for treatmentof congestive heart failure and other conditions

According to one embodiment, a protective device for use in congestive heart failure treatments, and other treatments, includes a control mechanism, an elongate shaft, and a protective plate. The control mechanism is coupled with a proximal end of the elongate shaft and the protective plate is pivotably coupled with a distal end of the elongate shaft.
Bioventrix, Inc.

Remote pericardial hemostasis for ventricular access and reconstruction or other organ therapies

Embodiments described herein provide devices, systems, and methods that reduce the distance between two locations in tissue, often for treatment of congestive heart failure. For example, an anchor of an implant system may, when the implant system is fully deployed, reside within the right ventricle in engagement with the ventricular septum.
Bioventrix, Inc.

Renal pump

Apparatus and methods are described including identifying a subject as suffering from a condition selected from the group consisting of: cardiac dysfunction, congestive heart failure, reduced renal blood flow, increased renal vascular resistance, arterial hypertension, and kidney dysfunction. In response thereto, blood pressure within a renal vein (32) of the subject is reduced, by placing a blood pump (150) inside the subject's renal vein and activating the impeller to pump blood from the renal vein into the subject's vena cava (26).
Magenta Medical Ltd.

Steerable lesion excluding heart implants for congestive heart failure

Devices, systems, and methods for treating a heart of a patient may make use of one or more implant structures which limit a size of a chamber of the heart, such as by deploying a tensile member to bring a wall of the heart toward (optionally into contact with) a septum of the heart.. .
Bioventrix, Inc.

Intelligent health home monitoring system supporting congestive heart failure self-care

A telehealth system for monitoring the health of a chf patient has a communication application operating on an electronic device, in communication with a medical authority, a scale connected to the application and configured to provide weight of the patient, a glucometer connected to the application and configured to provide a glucose measurement of the patient, a blood pressure meter connected to the application and configured to provide a blood pressure measurement of the patient, a database in communication with the application configured to store the weight measurement, glucose measurement and blood pressure measurement data, a rule-based expert system in communication with the monitoring database and with the application, wherein the expert system provides a risk assessment based on the weight, glucose reading and blood pressure of the patient.. .

Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration

Methods of treating bendamustine responsive conditions in patients having fluid and/or sodium intake restrictions are disclosed. The methods include identifying patients having such restrictions and in need of bendamustine, and then administering thereto a bendamustine-containing composition in a volume of about 120 ml or less intravenously over a period of about 15 minutes or less.
Eagle Pharmaceuticals, Inc.

Methods

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, creutzfeldt-jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.. .
Aeromics, Llc

Method and system for monitoring congestive heart failure risk of a cardiac patient

A method for monitoring a patient after release from a health care facility includes: monitoring, using a control module, at least one characteristic of the patient in an outpatient setting; based on the one or more characteristics, determining a risk of readmission; and when the risk of readmission is above a certain threshold, automatically generating a notification to a healthcare provider to provide intervention. A system for monitoring the patient includes: a sensor configured to measure at least one characteristic of the patient in an outpatient setting; and a control module in communication with the sensor, the control module configured to: monitor the at least one characteristic via the at least one sensor; based on the one or more characteristics, determine a risk of readmission; and when the risk of readmission is above a certain threshold, automatically generate a notification to a healthcare provider to provide intervention..
Nikias Group, Llc

Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (ppar) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension.
Ardelyx, Inc

Bifidobacteria for treating cardiac conditions

This invention relates to new uses of bifidobacteria (particularly, although not exclusively, probiotic bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction and congestive heart failure..
Dupont Nutrition Biosciences Aps

Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (ppar) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension.
Ardelyx, Inc

Prodrug of an ice inhibitor

Compound i is useful for treating il-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, alzheimer's disease, myocardial infarction, congestive heart failure, huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.. .



Congestive Heart Failure topics:
  • Congestive Heart Failure
  • Hypertension
  • Dysfunction
  • Vascular Disease
  • Cardiovascular
  • Cardiovascular Disease
  • Atherosclerosis
  • Inflammation
  • Endothelial
  • Nephropathy
  • Endothelial Dysfunction
  • Steoporosis
  • Osteoporosis
  • Renal Failure
  • Atrial Fib


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Congestive Heart Failure for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Congestive Heart Failure with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.4415

    file did exist - 2997

    1 - 1 - 50